Immunotherapy in lung cancer

Survival rates for metastatic lung cancer including non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) are poor with 5-year survival of less than 5%. The use of molecular targeted therapies has improved median overall survival (OS) in a limited group of NSCLC patients whose tumors...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Transl Lung Cancer Res
Main Authors: Massarelli, Erminia, Papadimitrakopoulou, Vassiliki, Welsh, James, Tang, Chad, Tsao, Anne S.
Formato: Artigo
Idioma:Inglês
Publicado: Pioneer Bioscience Publishing Company 2014
Assuntos:
Review Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4367607/
https://ncbi.nlm.nih.gov/pubmed/25806281
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2218-6751.2014.01.01
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares